Next generation topoisomerase I inhibitors: Rationale and biomarker strategies
about
Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transportersImplication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage responseDrugging topoisomerases: lessons and challengesChemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cellsSolvent dependency of the UV-Vis spectrum of indenoisoquinolines: role of keto-oxygens as polarity interaction probesExon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intronThe structure–activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding modeSynthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: Investigating the hypothesis of shared structure–activity relationshipsDNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial InhibitionSequential Cu(I)/Pd(0)-catalyzed multicomponent coupling and annulation protocol for the synthesis of indenoisoquinolines.Up-regulation of p21 and TNF-alpha is mediated in lycorine-induced death of HL-60 cells.Design, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors.Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma.Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitorsThe indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.Immobilizing topoisomerase I on a surface plasmon resonance biosensor chip to screen for inhibitorsEvaluation of two models for human topoisomerase I interaction with dsDNA and camptothecin derivativesCell deathProteomic analysis of nuclei isolated from cancer cell lines treated with indenoisoquinoline NSC 724998, a novel topoisomerase I inhibitor.Rottlerin potentiates camptothecin-induced cytotoxicity in human hormone refractory prostate cancers through increased formation and stabilization of topoisomerase I-DNA cleavage complexes in a PKCδ-independent pathway.Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissuesNetwork signatures of survival in glioblastoma multiforme.Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity.Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitorsPotentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762.A Selective Small Molecule DNA2 Inhibitor for Sensitization of Human Cancer Cells to ChemotherapyRNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.Indotecan (LMP400) and AM13-55: two novel indenoisoquinolines show potential for treating visceral leishmaniasis.Identification, synthesis, and biological evaluation of metabolites of the experimental cancer treatment drugs indotecan (LMP400) and indimitecan (LMP776) and investigation of isomerically hydroxylated indenoisoquinoline analogues as topoisomerase ICharacterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations3EZ,20Ac-ingenol, a catalytic inhibitor of topoisomerases, downregulates p-Akt and induces DSBs and apoptosis of DT40 cells.Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity12-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridines as novel topoisomerase I-targeting antitumor agents.Novel topoisomerase I-targeting antitumor agents synthesized from the N,N,N-trimethylammonium derivative of ARC-111, 5H-2,3-dimethoxy-8,9-methylenedioxy-5-[(2-N,N,N-trimethylammonium)ethyl]dibenzo[c,h][1,6]naphthyridin-6-one iodide.4-Pregnen-21-ol-3,20-dione-21-(4-bromobenzenesulfonate) (NSC 88915) and related novel steroid derivatives as tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors.Novel camptothecin derivatives as topoisomerase I inhibitors.Sequence selectivity of the cleavage sites induced by topoisomerase I inhibitors: a molecular dynamics study.Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400).Synthesis and biological evaluation of new carbohydrate-substituted indenoisoquinoline topoisomerase I inhibitors and improved syntheses of the experimental anticancer agents indotecan (LMP400) and indimitecan (LMP776).
P2860
Q24648348-4BAABDBE-AF0A-4365-B428-AEB405E188E7Q24650185-172D15D7-9FF1-4406-9F72-ACDA05E3CDA6Q27000099-694EFD21-3793-4A2E-AC07-85AD08E29D5DQ28481351-64BC691F-D5E8-453F-B908-F4C426AEC83FQ28533825-BB340FB6-FD2E-410B-9009-17B40F3E44B5Q28749651-9CB2E7D1-3180-4B93-8A62-0FADED1EF640Q29028715-E68C6629-4A11-402C-8C38-86757DA258FEQ29038255-42C5ECC5-7219-40FF-A765-3F2ED41FDAACQ29400901-AEDD45BC-F7D1-4445-A5BF-C2EBC2AFA7A6Q33401654-FA9B6A57-40E7-47E2-92A7-04BB8708848FQ33648570-39FBA76C-7201-47CC-86F7-312B22739521Q33662415-2F1B4C7C-8122-491F-A191-95EDC9097D16Q33691241-78CA19C5-437A-408A-B4D7-D5A0A3DA61CFQ33725863-4C7FD061-FA45-493D-BCCD-0A43852FCC4FQ33925798-2709FFF8-B432-4DE9-BB4A-3E74AC93EFA8Q33968743-6D524976-2B4B-480F-ADBA-AECBFE55743AQ34017703-EB9C3AA5-0E76-4C96-A7CF-5884C839D788Q34019760-42C7C860-E929-4033-A26C-0444E9A6BF21Q34049926-993C13DB-F51E-4625-ACB1-A07941459E65Q34401367-93D9A744-B832-4DA9-BCA2-BFFB11EF6429Q34531543-7E95B198-9AD1-4C49-9ACB-7B3D8913D0CBQ34998178-E340CE58-CA71-471A-9504-076F748C59EAQ35152039-CD40CE5A-149D-4F38-A3BB-A3789CE6DA3DQ35161740-83AD2185-955C-4090-BBF1-966CADB4E11BQ35167579-44902DE9-08C4-4894-A110-9CD5EFB5DAB5Q35782905-E7AA5BAB-E853-4677-90E4-58A847700B8BQ36025829-651860C4-E5DA-4604-BF8E-842A6CC99C67Q36108221-1617C81D-2E3D-4123-A80B-C2B9013E35BAQ36276947-DA1272C5-E345-4699-BEAD-F94705714434Q36525254-F113946F-B79B-43E4-90DC-E036EA4C03EBQ36749303-633620A5-29AE-487B-91B6-348AE60F8E35Q37064521-3D6F24FF-F3C7-44DA-B46E-F7E513528CCFQ37309374-6E786DDD-3462-4C4C-BA94-D04495C7B90FQ37363598-1BD880B7-D322-4C10-B636-DE0FFD3D13A7Q37396799-2BEBC633-6516-45E7-9202-37AB56E78910Q37445367-EDBCB1C9-5A6F-4AF8-9856-00B3B1515DDBQ37481337-EE83F816-3A0D-4D56-A30A-DD7CD25C8834Q37528750-8D5EA5A8-DFE9-4267-8F63-58EA76A5266FQ37652515-F188923A-7EAF-4BE2-8E6B-4F9F636AF1F7Q37697354-A4402E55-091B-4B6C-8F43-4A2157F56C96
P2860
Next generation topoisomerase I inhibitors: Rationale and biomarker strategies
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Next generation topoisomerase I inhibitors: Rationale and biomarker strategies
@ast
Next generation topoisomerase I inhibitors: Rationale and biomarker strategies
@en
type
label
Next generation topoisomerase I inhibitors: Rationale and biomarker strategies
@ast
Next generation topoisomerase I inhibitors: Rationale and biomarker strategies
@en
prefLabel
Next generation topoisomerase I inhibitors: Rationale and biomarker strategies
@ast
Next generation topoisomerase I inhibitors: Rationale and biomarker strategies
@en
P3181
P1476
Next generation topoisomerase I inhibitors: Rationale and biomarker strategies
@en
P2093
Beverly A. Teicher
P304
P3181
P356
10.1016/J.BCP.2007.10.016
P407
P577
2008-03-01T00:00:00Z